A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
On March 4, 2025, the World Obesity Atlas 2025 was published by the World Obesity Federation and reported that the total number of adults living with obesity is now projected to increase by more than 115% between 2010 and 2030 (from 524 million to 1.…
Previous reports from our laboratory describing the formation of myofibrils in cultured embryonic cardiac and skeletal muscle cells have proposed that myofibrillogenesis occurs in three steps of increasing protein organization: beginning with premyof…
The rapid and widespread clinical adoption of highly effective incretin-mimetic drugs (IMDs), particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the updating of clinical practice guidelines. Consequently, many patient…
BACKGROUND: Obesity has emerged as a global health crisis, with its prevalence having increased alarmingly over recent decades. There is significant damage to pancreatic islets due to obesity, as well as metabolic syndrome. Improving the function of…
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated efficacy for weight loss and glycemic control in patients with obesity and type 2 diabetes mellitus, but data are limited for patients with end-stage kidney disease on dialysis…
BACKGROUND: In patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), sodium-glucose cotransporter 2 (SGLT2) inhibitors, semaglutide (glucagon-like peptide-1 [GLP-1] agonist), and finerenone (non-steroidal mineralocorticoid receptor an…
Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and weight management, are known for their metabolic benefits but may have unrecognized side effects. This study investigates the association between GLP-1 recep…
BACKGROUND AND AIMS: Incretin-based therapies, including glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, are essential treatments in diabetes management due to their efficacy in glycemic control an…
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic disorder with serious complications. Semaglutide, a GLP-1 receptor agonist, improves glycemic control and weight but is limited by gastrointestinal (GI) side effects, notably nausea, vomiting,…
Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for…
BACKGROUND: Social media has been extensively used by the public to seek information and share views on health issues. Recently, the proper and off-label use of semaglutide drugs for weight loss has attracted huge media attention and led to temporary…
Semaglutide is a lipopeptide with important applications in the treatment of diabetes, obesity, and other conditions. This class of drug (glucagon-like peptide-1 agonists and other lipidated peptides) may be susceptible to aggregation due to the tend…
Glucagon-like-peptide-1 (GLP-1) agonists are commonly used to improve glycemic control and promote weight loss in individuals with type 2 diabetes mellitus (T2DM) and/or obesity. However, there is a paucity of evidence regarding GLP-1 agonist use in…
Loss of lean mass is a potential concern for semaglutide-induced weight loss. This study indicates that semaglutide has unexpected effects on skeletal muscle mass and strength in mice, demonstrating a need to more carefully assess these effects in hu…
Diabetic neuropathy (DN) remains a major clinical burden, characterized by progressive sensory dysfunction, pain, and impaired quality of life. Despite the available symptomatic treatments, there is a pressing need for disease-modifying therapies. In…
BACKGROUND: The prevalence of heart failure with preserved ejection fraction (HFpEF) increases with age, and older adults with HFpEF have worse physical function, quality of life, and clinical outcomes. Semaglutide demonstrated efficacy in the treatm…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity. However, it remains inconclusive whether the combination of lifestyle modifications and GLP-1RA interventions can lead to greater weight loss and…
Type 2 diabetes significantly increases cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events, heart failure hospitalizations, and death. However, the comparison among GLP-1 RAs on cardio…
PURPOSE: This study aimed to investigate changes in muscle mass and strength among older adults with type 2 diabetes who were treated with Semaglutide. METHODS: This was a retrospective cohort study comparing elderly patients with type 2 diabetes rec…